Drug Trial Radar · NCT06724614
Efficacy and Safety of VDPHL01 in Males With AGA
Last checked: Nov 19, 2026Latest source record: Nov 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
480
Planned (sponsor's estimate)
Start
Nov 6, 2024
Primary completion
Feb 2026
Study completion Sep 2026
Sponsor
- Lead sponsor
- Veradermics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 9, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety and efficacy of VDPHL01 in male subjects with Androgenetic Alopecia (AGA). AGA (or male pattern baldness) is a genetic disorder caused by an excessive (too much) hair follicle response to androgens (hormone) that causes hair loss. VDPHL01 8.5 mg Tablet is an investigational oral drug to treat male pattern baldness. This multi-center, double blind, study will last about 13 months and includes 11 study visits (screening, baseline (day 1), week 2, month 1, month 2, month 4, month 6, month 8, month 10, month 12, month 13). The first 7 visits will be part of the placebo-controlled period. The next 3 visits will be part of the treatment extension phase. All subjects will receive active drug in the treatment extension phase.
Conditions
- Androgenetic Alopecia
- AGA
- Male Pattern Baldness
Interventions
VDPHL01Drug
VDPHL01 Extended Release (ER) Tablet
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Changes in non-vellus Target Area Hair Counts (TAHC)Time frame: Month 6
- Subjects Evaluation of Treatment BenefitTime frame: Month 6
Locations
44 sites in 1 country. Site status is shown where the registry gives one.
Site 36
Birmingham, Alabama
Site 28
Phoenix, Arizona
Site 30
Fort Smith, Arkansas
Site 35
Rogers, Arkansas
Site 07
Fountain Valley, California
Site 02
Fremont, California
Site 34
Sherman Oaks, California
Site 21
Vista, California
Site 05
Castle Rock, Colorado
Site 24
Englewood, Colorado
Site 17
Aventura, Florida
Site 25
Brandon, Florida
Site 42
Hollywood, Florida
Site 03
Tampa, Florida
Site 43
Atlanta, Georgia
Site 31
Boise, Idaho
Site 23
Rolling Meadows, Illinois
Site 15
Indianapolis, Indiana
Site 32
New Albany, Indiana
Site 27
West Lafayette, Indiana
Site 41
Baton Rouge, Louisiana
Site 13
Covington, Louisiana
Site 12
Metairie, Louisiana
Site 22
Brighton, Massachusetts
Site 26
Clarkston, Michigan
Site 06
New Brighton, Minnesota
Site 18
Hackensack, New Jersey
Site 37
Kew Gardens, New York
Site 38
New York, New York
Site 39
Boardman, Ohio
Site 11
Columbus, Ohio
Site 08
Broomall, Pennsylvania
Site 10
Plymouth Meeting, Pennsylvania
Site 20
Greensville, South Carolina
Site 09
Knoxville, Tennessee
Site 16
Murfreesboro, Tennessee
Site 04
Nashville, Tennessee
Site 40
Bellaire, Texas
Site 44
Dallas, Texas
Site 14
Houston, Texas
Showing 40 of 44 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.